New Data Supporting VBI's Prophylactic Cytomegalovirus Vaccine Candidate (VBI-1501A)
VBI Vaccines, Inc.
("VBI") (Nasdaq: VBIV) presented new data last week that demonstrates continued
support for the development of the company's prophylactic CMV vaccine
The oral presentation, A Prophylactic Human Cytomegalovirus (HCMV) Vaccine
Designed to Prevent Congenital Infection Using Enveloped Virus-Like Particles
(eVLPs), was delivered by Dr. David E. Anderson, VBI's Senior Vice President
of Research, at the 54th Interscience Conference on Antimicrobial Agents and
Chemotherapy (ICAAC) held in Washington, D.C. The presentation, previously
under embargo, is now available for download here:
"The limited potency and durability of immunity induced with past CMV vaccine
candidates have hindered their potential efficacy. VBI's preclinical animal
data demonstrates that VBI-1501A has substantially improved potency and
durability, at levels now exceeding a benchmark for naturally acquired
immunity. Technology transfer to the contract manufacturer of our toxicology
and clinical batches of VBI-1501A is currently on track to support an IND
submission and phase I start in Q4 2015," commented Dr. Anderson.
Now in its 54^th year, ICAAC is a leading conference on antimicrobial agents
and infectious diseases and showcases the latest-breaking science and lectures
from top researchers around the world. ICAAC brings together the field's
foremost leaders to discuss the state of infection control and prevention on a
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.